Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
TORRENT PHARMA | SANOFI INDIA | TORRENT PHARMA/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.4 | 42.1 | 81.6% | View Chart |
P/BV | x | 8.7 | 8.6 | 101.4% | View Chart |
Dividend Yield | % | 0.7 | 1.0 | 68.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TORRENT PHARMA Mar-19 |
SANOFI INDIA Dec-18 |
TORRENT PHARMA/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,964 | 6,840 | 28.7% | |
Low | Rs | 1,245 | 4,630 | 26.9% | |
Sales per share (Unadj.) | Rs | 453.4 | 1,203.1 | 37.7% | |
Earnings per share (Unadj.) | Rs | 25.8 | 165.3 | 15.6% | |
Cash flow per share (Unadj.) | Rs | 62.3 | 209.9 | 29.7% | |
Dividends per share (Unadj.) | Rs | 17.00 | 84.00 | 20.2% | |
Dividend yield (eoy) | % | 1.1 | 1.5 | 72.3% | |
Book value per share (Unadj.) | Rs | 279.2 | 963.6 | 29.0% | |
Shares outstanding (eoy) | m | 169.22 | 23.03 | 734.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.5 | 4.8 | 74.2% | |
Avg P/E ratio | x | 62.2 | 34.7 | 179.3% | |
P/CF ratio (eoy) | x | 25.8 | 27.3 | 94.3% | |
Price / Book Value ratio | x | 5.7 | 6.0 | 96.6% | |
Dividend payout | % | 65.9 | 50.8 | 129.7% | |
Avg Mkt Cap | Rs m | 271,513 | 132,078 | 205.6% | |
No. of employees | `000 | 13.6 | 3.3 | 411.9% | |
Total wages/salary | Rs m | 14,038 | 4,068 | 345.1% | |
Avg. sales/employee | Rs Th | 5,642.6 | 8,393.8 | 67.2% | |
Avg. wages/employee | Rs Th | 1,032.4 | 1,232.4 | 83.8% | |
Avg. net profit/employee | Rs Th | 320.9 | 1,153.0 | 27.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 76,728 | 27,708 | 276.9% | |
Other income | Rs m | 571 | 897 | 63.6% | |
Total revenues | Rs m | 77,299 | 28,605 | 270.2% | |
Gross profit | Rs m | 19,831 | 6,235 | 318.1% | |
Depreciation | Rs m | 6,177 | 1,027 | 601.5% | |
Interest | Rs m | 5,038 | 7 | 71,964.3% | |
Profit before tax | Rs m | 9,187 | 6,098 | 150.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -3,570 | 0 | - | |
Tax | Rs m | 1,254 | 2,292 | 54.7% | |
Profit after tax | Rs m | 4,363 | 3,806 | 114.6% | |
Gross profit margin | % | 25.8 | 22.5 | 114.9% | |
Effective tax rate | % | 13.6 | 37.6 | 36.3% | |
Net profit margin | % | 5.7 | 13.7 | 41.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 50,375 | 15,922 | 316.4% | |
Current liabilities | Rs m | 51,653 | 6,235 | 828.4% | |
Net working cap to sales | % | -1.7 | 35.0 | -4.8% | |
Current ratio | x | 1.0 | 2.6 | 38.2% | |
Inventory Days | Days | 92 | 64 | 144.7% | |
Debtors Days | Days | 68 | 21 | 327.3% | |
Net fixed assets | Rs m | 83,648 | 7,539 | 1,109.5% | |
Share capital | Rs m | 846 | 230 | 367.9% | |
"Free" reserves | Rs m | 46,397 | 21,962 | 211.3% | |
Net worth | Rs m | 47,244 | 22,192 | 212.9% | |
Long term debt | Rs m | 39,129 | 0 | - | |
Total assets | Rs m | 141,209 | 29,839 | 473.2% | |
Interest coverage | x | 2.8 | 872.1 | 0.3% | |
Debt to equity ratio | x | 0.8 | 0 | - | |
Sales to assets ratio | x | 0.5 | 0.9 | 58.5% | |
Return on assets | % | 6.7 | 12.8 | 52.1% | |
Return on equity | % | 9.2 | 17.2 | 53.8% | |
Return on capital | % | 12.3 | 27.5 | 44.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 22,103 | 7,587 | 291.3% | |
Fx outflow | Rs m | 5,522 | 7,145 | 77.3% | |
Net fx | Rs m | 16,581 | 442 | 3,751.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 17,981 | 3,739 | 480.9% | |
From Investments | Rs m | -2,413 | -731 | 330.1% | |
From Financial Activity | Rs m | -13,145 | -1,972 | 666.6% | |
Net Cashflow | Rs m | 2,380 | 1,036 | 229.7% |
Indian Promoters | % | 71.5 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 7.0 | 14.4 | 48.8% | |
FIIs | % | 12.6 | 14.6 | 86.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 8.8 | 10.5 | 83.8% | |
Shareholders | 26,511 | 15,184 | 174.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare TORRENT PHARMA With: ELDER PHARMA FDC SUN PHARMA STRIDES PHARMA SCIENCE TTK HEALTHCARE
Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More